Document is current

Article History

Received: 24 January 2024

Accepted: 16 July 2024

First Online: 4 August 2024

Declarations

:

: AMK, RER, KFK, AP, LK, SD, DG, DEL, JFB, MNF, and MD have no disclosures. SBG is a consultant for Procter & Gamble and Sermonix Pharmaceuticals and receives research funding from Paxman and Sprout Pharmaceuticals. TAT is a consultant for Agendia, AstraZeneca, Athenex, Ayala Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo, Eisai, Ellipses Pharma, Exact Sciences, Foundation Medicine, Fuji Pharma, Genentech/Roche, Gilead Sciences, Ionis Pharmaceuticals, ITeos Therapeutics, Merck, Pfizer, Puma Biotechnology, and Seattle Genetics. TAT receives research funding from Astellas Pharma, AstraZeneca, Ayala Pharmaceuticals, Carrick Pharm, Daiichi Sankyo, Eisai, Genentech/Roche, Immunomedics, Innocrin Pharma, Novartis, and Pfizer. AG receives research funding from BioAtla, Bristol-Myers Squibb, Innocrin Pharma, Merck, Novartis, OncoTherapy Science, Pfizer, Roche, and Zenith Epigenetics. BMD is employed by Canfield Scientific, Inc. VR is a consultant for Inhabit Brands, Inc. JS is a consultant for Shook, Hardy and Bacon, Pfizer and Lilly. AM receives research funding from Incyte Corporation and Amryt Pharma; serves on the advisory board for Blueprint Medicines, Alira Health, and Janssen; and receives royalties from UpToDate. MEL has a consultant role with Johnson and Johnson, Novocure, QED, Bicara, Janssen, Novartis, F. Hoffmann-LaRoche AG, EMD Serono, Astrazeneca, Innovaderm, Deciphera, DFB, Azitra, Kintara, RBC/La Roche Posay, Trifecta, Varsona, Genentech, Loxo, Seattle Genetics, Lutris, On Quality, Azitra, Roche, Oncoderm, NCODA, and Apricity. MEL receives research funding from Lutris, Paxman, Novocure, J&J, US Biotest, OQL, Novartis, and Astrazeneca.

: This is a retrospective study. The Institutional Review Board of Memorial Sloan Kettering Cancer Center has confirmed that no ethical approval is required.